Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-κB dependent AP-1-mediated ICAM-1 expression in breast cancer cells

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Ahmed, Mansoor ^a   Kundu, Gopal C ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MAMMALIAN TARGET OF RAPAMYCIN; OSTEOPONTIN; RAPAMYCIN; S6 KINASE; TRANSCRIPTION FACTOR AP 1; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; TRANSACTIVATION; TRANSCRIPTION REGULATION; BIOSYNTHESIS; BREAST TUMOR; ENZYME ACTIVATION; FEMALE; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; OSTEOPONTIN; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR CROSS-TALK; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 77951966160     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-101     Document Type: Article

References (40)

1. Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, Markward NJ, Ebner F, Kiechle M, Schwarz-Boeger U, Griffiths LR, Ulbrich C, Chrobok K, Forster G, Praetorius GM, Meyer P, Rehbock J, Cantor CR, Nelson MR, Braun A. Large scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 2004, 64:8906-10. 10.1158/0008-5472.CAN-04-1788, 15604251.
2. Beckmann MW, Niederacher D, Schnürch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997, 75:429-39. 10.1007/s001090050128, 9231883.
3. Borg A, Ferno M, Peterson C. Predicting the future of breast cancer. Nat Med 2003, 9:16-8. 10.1038/nm0103-16, 12514712.
4. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000, 11:279-303. 10.1177/10454411000110030101, 11021631.
5. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003, 278:28593-606. 10.1074/jbc.M303445200, 12771144.
6. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 2004, 279:11051-64. 10.1074/jbc.M310256200, 14704150.
7. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrixmetalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001, 276:44926-35. 10.1074/jbc.M103334200, 11564733.
8. Philip S, Kundu GC. Osteopontin induces nuclear factor-kappa B-mediated promatrix metalloproteinase-2 activation through Ikappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003, 278:14487-97. 10.1074/jbc.M207309200, 12473670.
9. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004, 279:38921-35. 10.1074/jbc.M404674200, 15247285.
10. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16:79-87. 10.1016/j.tcb.2005.12.005, 16406521.
11. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005, 14:313-28. 10.1517/13543784.14.3.313, 15833062.
12. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-45. 10.1101/gad.1212704, 15314020.
13. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologus to yeast TORs. Cell 1994, 78:35-43. 10.1016/0092-8674(94)90570-3, 7518356.
14. Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 2000, 275:7416-23. 10.1074/jbc.275.10.7416, 10702316.
15. Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999, 344:427-31. 10.1042/0264-6021:3440427, 1220660, 10567225.
16. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001, 294:1102-05. 10.1126/science.1063518, 11691993.
17. Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 2002, 277:20104-12. 10.1074/jbc.M201745200, 11914378.
18. Weng QP, Andrabi K, Klippel A, Kozlowski MT, Williams LT, Avruch J. Phosphatidylinositol 3-kinase signals activation of p70 S6 kinase in situ through site-specific p70 phosphorylation. Proc Natl Acad Sci USA 1995, 92:5744-8. 10.1073/pnas.92.12.5744, 41773, 7777579.
19. Ferrari S, Bannwarth W, Morley SJ, Totty NF, Thomas G. Activation of p70S6k is associated with phosphorylation of four clustered sites displaying Ser/Thr-Pro motifs. Proc Natl Acad Sci USA 1992, 89:7282-6. 10.1073/pnas.89.15.7282, 49690, 1496022.
20. Han JW, Pearson RB, Dennis PB, Thomas G. Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites. J Biol Chem 1995, 270:21396-403. 10.1074/jbc.270.41.23934, 7545671.
21. Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, Li Z, Evans DB, Abbruzzese JL, Chiao PJ. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 2004, 24:7806-19. 10.1128/MCB.24.17.7806-7819.2004, 507000, 15314185.
22. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26. 10.1038/nrd1279, 14708018.
23. Minhajuddin M, Fazal F, Bijli KM, Amin MR, Rahman A. Inhibition of mammalian target of rapamycin potentiates thrombin-induced intercellular adhesion molecule-1 expression by accelerating and stabilizing NF-kappa B activation in endothelial cells. J Immunol 2005, 174:5823-9.
24. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol 2002, 22:6321-35. 10.1128/MCB.22.18.6321-6335.2002, 135624, 12192032.
25. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006, 6:819-30. 10.2174/156652406779010803, 17168734.
26. Moh MC, Zhang C, Luo C, Lee LH, Shen S. Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol Chem 2005, 280:27366-74. 10.1074/jbc.M500852200, 15917256.
27. Fiore E, Fusco C, Romero P, Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002, 21:5213-23. 10.1038/sj.onc.1205684, 12149643.
28. Zhang X, Wu D, Jiang X. Icam-1 and acute pancreatitis complicated by acute lung injury. J Pancreas 2009, 10:8-14.
29. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, Denissenko MF. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005, 26:943-50. 10.1093/carcin/bgi070, 15774488.
30. Hirohashi S, Kanai Y. Cell adhesion system and human cancer morphogenesis. Cancer Sci 2003, 94:575-81. 10.1111/j.1349-7006.2003.tb01485.x, 12841864.
31. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002, 62:3417-27.
32. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 2010, 31:192-200. 10.1093/carcin/bgp289, 19926637.
33. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, Colucci S, Zambonin-Zallone A, Ross FP, Teitelbaum SL, Cheresh D. Binding of osteopontin to the osteoclast integrin alpha v beta 3. Osteoporos Int 1993, 3:132-5. 10.1007/BF01621887, 8461540.
34. Panda D, Kundu GC, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K, Mukherjee AB. Potential roles of osteopontin and alpha v beta 3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci USA 1997, 94:9308-13. 10.1073/pnas.94.17.9308, 23171, 9256478.
35. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003, 3:371-7. 10.1016/S1471-4892(03)00071-7, 12901945.
36. Pullen N, Thomas G. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997, 410:78-82. 10.1016/S0014-5793(97)00323-2, 9247127.
37. Moser BA, Dennis PB, Pullen N, Pearson RB, Williamson NA, Wettenhall RE, Kozma SC, Thomas G. Dual requirement for a newly identified phosphorylation site in p70s6k. Mol Cell Biol 1997, 17:5648-55. 232413, 9271440.
38. Adwan H, Bauerle TJ, Berger MR. Down regulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther 2004, 11:109-20. 10.1038/sj.cgt.7700659, 14647232.
39. Adwan H, Bäuerle T, Najajreh Y, Elazer V, Golomb G, Berger MR. Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol 2004, 24:1235-44.
40. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 2008, 68:152-61. 10.1158/0008-5472.CAN-07-2126, 18172307.